Yong Yang

Prediction of 5‐year overall survival of diffuse large B‐cell lymphoma on the pola‐R‐CHP regimen based on 2‐year event‐free survival and progression‐free survival

Shulian Wang, Yueping Liu, H. Jing, 2024, Cancer medicine.

The role of radiotherapy in patients with refractory Hodgkin's lymphoma after treatment with brentuximab vedotin and/or immune checkpoint inhibitors

Yuping Lin, Siqin Liao, Y. Qiu, 2023, Journal of the National Cancer Center.

Association of overall survival benefit of radiotherapy with progression-free survival after chemotherapy for diffuse large B-cell lymphoma: A systematic review and meta-analysis

Shulian Wang, Yueping Liu, Yexiong Li, 2024, Journal of the National Cancer Center.

Optimizing the combination of chemotherapeutic drugs along with radiotherapy for extranodal NK/T-cell lymphoma

Yu-jing Zhang, Hua Wang, Ying Wang, 2024, Therapeutic advances in medical oncology.